What Is IGF-1 (Insulin-Like Growth Factor 1)? Normal vs Optimal Range Explained

The lab range for IGF-1 spans 50–300 ng/mL—a sixfold spread that encompasses growth hormone deficiency at one extreme and potentially dangerous cellular overstimulation at the other. The CTD maps over 1,800 compound interactions affecting IGF-1 signaling pathways, reflecting how profoundly nutrition, sleep, exercise, medications, and metabolic status influence this growth factor. A 55-year-old man at 80 ng/mL sits within the lab-normal range but likely has functional GH deficiency—losing muscle mass, accumulating visceral fat, recovering poorly from exercise, and experiencing the accelerated aging phenotype that defined adult GH deficiency in endocrine literature. Conversely, values persistently above 300 ng/mL raise legitimate concern about cancer promotion, since IGF-1 directly stimulates cellular proliferation and inhibits programmed cell death. The optimal window of 150–250 ng/mL represents the functional sweet spot where anabolic repair processes remain active without fueling excessive growth.

The longevity community actively debates the ideal IGF-1 target, and the answer depends on individual context. PubMed indexes over 48,000 publications on IGF-1, with epidemiological analyses revealing a U-shaped mortality curve—both very low and very high IGF-1 levels associate with increased all-cause mortality. Populations with genetic IGF-1 deficiency (Laron syndrome) show remarkably low cancer rates but suffer from metabolic syndrome, obesity, and reduced quality of life, demonstrating that eliminating IGF-1 signaling is not the longevity solution some proponents suggest. Animal models showing lifespan extension from IGF-1 reduction do not translate cleanly to humans, where maintaining adequate IGF-1 supports bone density, cognitive function, cardiovascular health, and immune competence. Protein intake is the strongest dietary lever—animal protein stimulates IGF-1 more potently than plant protein, which explains why strict vegans often have lower IGF-1 levels.

Several medication classes and medical conditions alter IGF-1 independently of GH status. FAERS data document IGF-1 changes across over 60 medication entries, including corticosteroids that suppress GH secretion and estrogen-containing medications that modify hepatic IGF-1 production. Liver disease reduces IGF-1 because the liver is the primary production site—cirrhosis can cause profoundly low IGF-1 even with normal GH secretion. Malnutrition, particularly protein and calorie deficiency, lowers IGF-1 as the body downregulates growth pathways to conserve energy. Sleep deprivation reduces IGF-1 because the majority of GH secretion occurs during deep slow-wave sleep, and GH is the primary stimulus for hepatic IGF-1 production. Testing IGF-1 alongside IGFBP-3 (its primary binding protein) gives a more complete picture—the ratio reflects bioavailable free IGF-1 rather than total circulating levels.